FINGOLIMOD HYDROCHLORIDE (fingolimod hcl) by Novartis is metabolite, fingolimod-phosphate. Approved for relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease and 3 more indications. First approved in 2021.
Drug data last refreshed 18h ago
metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of…
Worked on FINGOLIMOD HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.